What Happened

Scholar Rock secured FDA approval for Isembyld (apitegromab), its first-ever product, for spinal muscular atrophy (SMA) in adults and children aged 2 and older who also receive SMN2-targeted therapies. The approval came two weeks ahead of the September 30 PDUFA deadline, following a prior rejection tied to a Novo Nordisk-owned fill-finish site in Bloomington, Indiana.

The phase 3 SAPPHIRE study showed a 2.2-point improvement on the Hammersmith Functional Motor Scale-Expanded versus SMN2 therapy alone, with 98% of patients continuing into the long-term extension study. Isembyld blocks myostatin to preserve muscle strength, and is set to ship in the coming days at a projected cost of $310,000 annually.

Who Is Affected

SMA affects roughly 10,000 children and adults in the U.S., and existing treatments from Novartis, Roche, and Biogen target the SMN2 gene. Isembyld is the first to directly target muscle atrophy, offering a complementary option for patients already on SMN2 therapies. For Scholar Rock, this approval transitions the company from clinical-stage to commercial-stage, impacting its operations, manufacturing partners, and market positioning.

Market Impact

• First commercial launch for Scholar Rock, creating immediate demand for launch services, distribution, and market access support.
• Projected $310K annual price tag positions Isembyld as a high-value specialty drug, requiring payer engagement and patient support programs.
• Shares rose 23% in after-market trading, reflecting investor confidence in the drug's commercial potential.
• Competitive landscape includes Novartis, Roche, and Biogen, but Isembyld's unique mechanism differentiates it in the SMA market.

What to Watch

Scholar

Related coverage

• H1 Partners with Novo Nordisk for AI-Driven Clinical Development
• Mirum Pharmaceuticals Wins FDA Approval for Atebrioz for Rare Bone Disorder FOP
• Bristol Myers cuts another 265 jobs tied to New Jersey headquarters
• Novo Nordisk workforce reduction reaches 13,000 amid R&D restructuring